WO1999036092A3 - Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells - Google Patents

Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells Download PDF

Info

Publication number
WO1999036092A3
WO1999036092A3 PCT/GB1999/000174 GB9900174W WO9936092A3 WO 1999036092 A3 WO1999036092 A3 WO 1999036092A3 GB 9900174 W GB9900174 W GB 9900174W WO 9936092 A3 WO9936092 A3 WO 9936092A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
target cells
albumin
ligand
hiv inhibition
Prior art date
Application number
PCT/GB1999/000174
Other languages
French (fr)
Other versions
WO1999036092A2 (en
Inventor
Paul Stuart O'shea
Original Assignee
Quadrant Healthcare Uk Ltd
Shea Paul Stuart O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Healthcare Uk Ltd, Shea Paul Stuart O filed Critical Quadrant Healthcare Uk Ltd
Priority to AU21752/99A priority Critical patent/AU2175299A/en
Publication of WO1999036092A2 publication Critical patent/WO1999036092A2/en
Publication of WO1999036092A3 publication Critical patent/WO1999036092A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

HIV infection may be prevented by using a material that does not bind lipids but binds preferentially to a receptor selected from the gp60 receptor and albumin receptors, on target cells. Such materials include albumin fragments having no lipid-binding domain.
PCT/GB1999/000174 1998-01-19 1999-01-19 Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells WO1999036092A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21752/99A AU2175299A (en) 1998-01-19 1999-01-19 Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9801070.5 1998-01-19
GBGB9801070.5A GB9801070D0 (en) 1998-01-19 1998-01-19 HIV inhibition

Publications (2)

Publication Number Publication Date
WO1999036092A2 WO1999036092A2 (en) 1999-07-22
WO1999036092A3 true WO1999036092A3 (en) 1999-10-28

Family

ID=10825503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000174 WO1999036092A2 (en) 1998-01-19 1999-01-19 Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells

Country Status (3)

Country Link
AU (1) AU2175299A (en)
GB (1) GB9801070D0 (en)
WO (1) WO1999036092A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930160D0 (en) 1999-12-22 2000-02-09 Biovector Solutions Limited Drug delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01217540A (en) * 1988-02-25 1989-08-31 Toshiba Corp Document preparing device
WO1994002505A1 (en) * 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
WO1997010850A1 (en) * 1995-09-21 1997-03-27 Andaris Limited Transcytosis vehicles and enhancers for drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01217540A (en) * 1988-02-25 1989-08-31 Toshiba Corp Document preparing device
WO1994002505A1 (en) * 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
WO1997010850A1 (en) * 1995-09-21 1997-03-27 Andaris Limited Transcytosis vehicles and enhancers for drug delivery

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AHMED A E E ET AL: "Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation.", IMMUNOLOGY, (1988) 64 (1), 45-50., XP002114016 *
DATABASE WPI Week 9042, Derwent World Patents Index; AN 90-317325, "New human serum albumin fragments-used to bond to medicines and for stable folding of protein(s)" *
GORDON ET AL.: "The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 11, November 1993 (1993-11-01), pages 1145 - 1156, XP002114010 *
JANSEN R W ET AL: "Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins.", MOLECULAR PHARMACOLOGY, (1991). VOL. 39, NO. 6, PP. 818-23. JOURNAL CODE: NGR. ISSN: 0026-895X., Department of Pharmacology and Therapeutics, Groningen University, The Netherlands., XP002114011 *
MALIK A B ET AL: "Lectin binding to gp60 decreases specific albumin binding and transport in pulmonary artery endothelial monolayers.", 75TH ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, ATLANTA, GEORGIA, USA, APRIL 21-25, 1991. FASEB (FE AM SOC EXP BIOL) J. (1991) 5 (4), A754., XP002114012 *
NIELSEN H ET AL: "Effect of genetic variation on the fatty acid- binding properties of human serum albumin and proalbumin.", BIOCHIMICA ET BIOPHYSICA ACTA, (1997 OCT 17) 1342 (2) 191-204., XP002114009 *
PATENT ABSTRACTS OF JAPAN vol. 14, no. 539 (C - 0782) 28 November 1990 (1990-11-28) *
PEREIRA F B ET AL: "Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti- HIV compounds.", AIDS RESEARCH AND HUMAN RETROVIRUSES, (1997). VOL. 13, NO. 14, PP. 1203-11. JOURNAL CODE: ART. ISSN: 0889-2229., Department of Biochemistry and Molecular Biology (Biomembrane Laboratory-CSIC), University of the Basque Country, Bilbao, Spain., XP002114018 *
SCHNITZER, JAN E. (1) ET AL: "Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium.", AMERICAN JOURNAL OF PHYSIOLOGY, (1992) VOL. 263, NO. 6 PART 2, PP. H1872-H1879., XP002114017 *
SCHNITZER, JAN E. (1) ET AL: "Antibodies to the albumin binding protein, albondin, inhibit transvascular transport of albumin in the rat lung.", FASEB JOURNAL, (1993) VOL. 7, NO. 3-4, PP. A902. MEETING INFO.: MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOLOGY '93 NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1993, XP002114013 *
SLEPUSHKIN V A ET AL: "Inhibition of human immunodeficiency virus type 1 ( HIV -1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV -1 transmembrane glycoprotein.", VIROLOGY, (1993). VOL. 194, NO. 1, PP. 294-301. JOURNAL CODE: XEA. ISSN: 0042-6822., D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, Moscow., XP002114015 *
TIRUPPATHI, CHINNASWAMY (1) ET AL: "Isolation and characterization of a cell surface albumin -bindin protein from vascular endothelial cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1996) VOL. 93, NO. 1, PP. 250-254., XP002114014 *

Also Published As

Publication number Publication date
AU2175299A (en) 1999-08-02
GB9801070D0 (en) 1998-03-18
WO1999036092A2 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
HK1033126A1 (en) Non-steroidal ligands for the estrogen receptor.
AU1621799A (en) Fungicidal compositions and methods, and compounds and methods for the preparation thereof
EP1074599B8 (en) Fluorescent granules, method for preparing the same and paper for preventing forgery using the fluorescent granules
PL346564A1 (en) Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
CA2334314A1 (en) Cellulose substrates with transparentized area
CA2234460A1 (en) Polyisocyanate composition
WO1999036092A3 (en) Hiv inhibition using ligand for gp60 receptor or albumin receptor on target cells
ID26857A (en) E-2- (4-CHLORO-1,2-DIFENYL-BUT-I-ENIL) PHENOCHY) ETHANOL AND THE PHARMACY COMPOSITIONS
AU7705196A (en) Pesticide compounds, compositions and process for the preparation thereof
MXPA02004943A (en) Polyolefin films suitable for institutional applications.
AU2067595A (en) Continuous boiler for organic materials, e.g. fish
DE69503143D1 (en) AGAINST CRYOLITE-RESISTANT, FIRE-RESISTANT MATERIAL
FR2712296B1 (en) Latex binder for coating composition.
DE29603683U1 (en) Device for processing cardboard sheets or the like. Patches
AU4221797A (en) Pyrimidine compounds, process for the preparation thereof, and pest controlling agents
AU4390797A (en) Device for "flipping a coin", or the like
EP0622377A3 (en) Amphotropic virus receptor.
Grava On the Cauchy problem for the Whitham equations
DE9405325U1 (en) Folder, stapler or the like
ES1032513Y (en) PERFECTED BUCKET FOR GARBAGE.
DE29512517U1 (en) Device for milling grooves, shadow gaps or the like.
AU7120896A (en) Cover for a side of a file, album or the like
Reinhart The likud will at least have an opposition
DE29709011U1 (en) Envelope, mailing bag or the like
DE9319600U1 (en) Folder, folder, collector or the like.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999901747

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999901747

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase